Gilead stock falls after lung cancer study results disappoint
Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.
Source link
- Why that ‘last mile’ of the inflation fight may be more challenging
- Stocks making the biggest moves midday: Vita Coco, Archer-Daniels-Midland, Gilead Sciences and more
